Published in J Am Diet Assoc on January 01, 2011
Nutrition and health technology assessment: when two worlds meet. Front Pharmacol (2015) 0.75
Adverse events associated with complementary and alternative medicine use in ovarian cancer patients. Integr Cancer Ther (2013) 0.75
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Markov models in medical decision making: a practical guide. Med Decis Making (1994) 8.14
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care (2008) 5.14
Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making (2000) 4.86
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess (2004) 3.73
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. Ann Epidemiol (2003) 2.64
Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst (2007) 2.37
Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst (2006) 2.19
When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst (2010) 1.95
Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial. Arch Intern Med (2008) 1.89
Cost of care for cancer in a health maintenance organization. Health Care Financ Rev (1997) 1.81
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med (2006) 1.57
An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care (2006) 1.51
Predictors of dietary change and maintenance in the Women's Health Initiative Dietary Modification Trial. J Am Diet Assoc (2007) 1.47
Determining transition probabilities: confusion and suggestions. Med Decis Making (1994) 1.35
Breast cancer: hormones and other risk factors. Maturitas (2001) 1.34
Additional self-monitoring tools in the dietary modification component of The Women's Health Initiative. J Am Diet Assoc (2004) 1.28
When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ (2004) 1.14
Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health (2007) 1.08
Improving the delivery of preventive services to Medicare beneficiaries. JAMA (2009) 1.00
Diet intervention methods to reduce fat intake: nutrient and food group composition of self-selected low-fat diets. J Am Diet Assoc (1990) 0.94
Measurement characteristics of 2 different self-monitoring tools used in a dietary intervention study. J Am Diet Assoc (2001) 0.88
Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am (2000) 0.88
Changes in food patterns during a low-fat dietary intervention in women. J Am Diet Assoc (1990) 0.86
The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care (1999) 0.86
Systematic review of literature on the cost-effectiveness of nutrition services. J Am Diet Assoc (2004) 0.85
Chemoprevention: drug pricing and mortality: the case of tamoxifen. Cancer (2006) 0.79
Estimating the survival benefits gained from providing national cancer genetic services to women with a family history of breast cancer. Br J Cancer (2004) 0.78
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
The case for early detection. Nat Rev Cancer (2003) 6.96
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst (2002) 6.28
Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation (2009) 5.82
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer (2007) 4.76
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med (2005) 4.24
Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res (2003) 4.13
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol (2008) 3.68
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials (2008) 3.24
Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care (2003) 3.21
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA (2003) 2.90
Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. Arch Intern Med (2010) 2.89
Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care (2008) 2.76
Physical activity and survival in postmenopausal women with breast cancer: results from the women's health initiative. Cancer Prev Res (Phila) (2011) 2.73
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Cadmium exposure and incident cardiovascular disease. Epidemiology (2013) 2.55
Pooled results from 5 validation studies of dietary self-report instruments using recovery biomarkers for energy and protein intake. Am J Epidemiol (2014) 2.53
Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. Circulation (2009) 2.49
Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension (2008) 2.44
Low-fat dietary pattern and change in body-composition traits in the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2010) 2.43
Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care (2003) 2.40
Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation (2006) 2.40
Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst (2007) 2.37
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Concordance of breast imaging reporting and data system assessments and management recommendations in screening mammography. Radiology (2002) 2.36
Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. Diabetes Care (2007) 2.33
Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res (2008) 2.24
Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. Am J Epidemiol (2003) 2.20
Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring) (2006) 2.17
Diabetes and lung cancer among postmenopausal women. Diabetes Care (2012) 2.17
The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst (2002) 2.14
Genetic determinants of lipid traits in diverse populations from the population architecture using genomics and epidemiology (PAGE) study. PLoS Genet (2011) 2.13
The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf (2013) 2.09
Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol (2002) 2.08
Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation (2002) 2.05
A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med (2007) 2.05
Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: the Strong Heart Study. J Clin Hypertens (Greenwich) (2011) 2.04
Evaluation and comparison of food records, recalls, and frequencies for energy and protein assessment by using recovery biomarkers. Am J Epidemiol (2011) 2.04
Noakes misses the point. S Afr Med J (2013) 2.04
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 2.01
Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol (2006) 2.00
Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. J Hypertens (2010) 2.00
Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women. Am J Epidemiol (2009) 1.98
Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation (2002) 1.94
Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One (2008) 1.93
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol (2008) 1.91
Short leukocyte telomere length predicts risk of diabetes in american indians: the strong heart family study. Diabetes (2013) 1.91
Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women's Health Initiative randomized controlled dietary modification trial. Arch Intern Med (2008) 1.89
Intensive care unit physician staffing: financial modeling of the Leapfrog standard. Crit Care Med (2004) 1.89
Associations of processed meat and unprocessed red meat intake with incident diabetes: the Strong Heart Family Study. Am J Clin Nutr (2012) 1.88
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol (2013) 1.85
Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer (2008) 1.84
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Cardiac markers of pre-clinical disease in adolescents with the metabolic syndrome: the strong heart study. J Am Coll Cardiol (2008) 1.81
Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum (2008) 1.80
High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study. J Am Coll Cardiol (2009) 1.79
Prevalence and prognostic significance of wall-motion abnormalities in adults without clinically recognized cardiovascular disease: the Strong Heart Study. Circulation (2007) 1.78
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol (2009) 1.77